Grace Therapeutics, Inc.
Grace Therapeutics, Inc. (Nasdaq: GRCE) is a clinical-stage pharmaceutical company developing reformulated medicines for rare and orphan diseases, using proprietary formulation and drug-delivery technologies to improve administration of existing compounds. Its lead candidate, GTx-104, is an injectable formulation of… From the company’s description.
In fiscal 2025, Grace Therapeutics, Inc. reported a net loss of $7.79M. Operations used $8.87M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Grace Therapeutics, Inc. does
In the company’s own words
Grace Therapeutics, Inc. (Nasdaq: GRCE) is a clinical-stage pharmaceutical company developing reformulated medicines for rare and orphan diseases, using proprietary formulation and drug-delivery technologies to improve administration of existing compounds. Its lead candidate, GTx-104, is an injectable formulation of nimodipine for intravenous infusion in patients with aneurysmal subarachnoid hemorrhage; the company submitted a new drug application, which the FDA returned with a Complete Response Letter citing manufacturing and nonclinical items. Grace also has GTx-102, an oral-mucosal betamethasone spray for ataxia-telangiectasia, and GTx-101, a topical bupivacaine spray for postherpetic neuralgia, but does not plan to resume internal development funding for either under its current operating plan and is evaluating licensing or partnership opportunities. The company focuses on drug development and has no reportable business segments described; it relies on third-party manufacturers and holds worldwide commercialization rights to its candidates. Its website is www.gracetx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PRINCETON, NJ
- Fiscal year end
- March
- CIK
- 1444192
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Grace Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Grace Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Grace Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Grace Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Grace Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”